Monoclonal lamprey VLR antibodies specific for mucin-type O-linked glycan core 1 - 4 structures
Monoclonal lamprey VLR antibodies specific for mucin-type O-linked glycan core 1 - 4 structures
批准号:
9464820
负责人:
Lovick Edward Cannon
金额:
$13.62万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-09-20 至 2018-12-31
关键词:
AchievementAdaptive Immune SystemAffinityAntibodiesAntibody RepertoireAntigen ReceptorsAntigensBindingBinding SitesBiological AssayBiological ProcessBloodC-terminalCancerousCarbohydratesCell AdhesionCellsCommon CoreCommunitiesComputer AnalysisDevelopmentDiseaseEnzyme-Linked Immunosorbent AssayFc ReceptorGeometryGoalsHagfishHealthHumanImmune SeraImmune systemImmunizationImmunizeImmunoglobulinsJawLampreysLeadLeucine-Rich RepeatLightLinkLymphocyteMalignant NeoplasmsMammalsMembraneModalityMolecular WeightMucinsNatural ImmunityPhasePolysaccharidesProductionReagentReceptor GeneResearchRoleSerineSignal TransductionSmall Business Technology Transfer ResearchSpecificityStructureSurfaceSurface AntigensTechnologyThreonineTissuesTn antigenTumor-Associated Carbohydrate AntigensVertebratesadaptive immunityantigen bindingbasebeta pleated sheetexpectationflexibilityglycosylationimmunogeniclymphocyte proliferationnovelnovel diagnosticsnovel therapeuticsphase 2 studypolypeptideprotein foldingreceptorreceptor bindingtraffickingtumor progression
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
We will develop and commercialize to the research community a new class of glycan-specific
binding reagents that incorporate the recognition function of variable lymphocyte receptors
(“VLRs”), the antigen receptors of the adaptive immune system of jawless vertebrates, lamprey
and hagfish. Such reagents are essential to detecting, localizing, quantifying, and establishing
biological function(s) of specific glycans in normal and disease cells and tissues, and may
additionally lead to development of new diagnostic and therapeutic modalities. The current
absence of such reagents is a significant barrier to further advancing an understanding the role
of glycans in health and disease. VLRs are composed of tandemly arranged highly diverse
leucine-rich repeat (LRR) structural motifs with diversity comparable to the human
immunoglobulin (Ig) antibody repertoire, and possess a distinctive more rigid binding site
geometry vs Ig antibodies that is entirely contained within a single polypeptide structure.
Vertebrates split into jawless and jawed vertebrate lineages approximately 550 million years
ago. The evolutionary separation of jawless vertebrates from humans and other mammals, and
the distinctive binding site geometry of VLRs potentially provide novel specificities and functions
not accessed with Ig antibodies. This expectation is supported by the discovery of VLRs that
bind carbohydrate antigens with affinity and specificity superior to that typically achieved with Ig
antibodies and indicate that VLRs are uniquely well-suited to binding and discriminating glycan
structures. The lamprey VLR-based immune system is potentially a transformative technology
for the rapid, high throughput production of specific binding reagents for the diverse glycan
structures that comprise the human glycome. With this phase 1 STTR application we will initiate
this application of the lamprey VLR-based immune system by demonstrating that lamprey can
be immunized to produce VLRs that specifically bind and discriminate each of the four most
common mucin-type O-linked glycan core structures in humans. In our follow-on phase 2
studies we will express these VLRs in a form that facilitates use for detecting, quantifying and
modulating the functions of the four mucin-type O-linked glycan core structures and provide
these reagents to the research community.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel targeted CAR-T multiple myeloma therapy
-
批准号:10821186
-
项目类别:
-
资助金额:$30.2万
-
财政年份:2023
-
负责人:Lovick Edward Cannon
-
依托单位:
Novel antibody polymer reagents for SARS-CoV-2 detection
-
批准号:10323707
-
项目类别:
-
资助金额:$25.65万
-
财政年份:2021
-
负责人:Lovick Edward Cannon
-
依托单位:
VLR-CART Cancer Immunotherapy
-
批准号:8833776
-
项目类别:
-
资助金额:$14.9万
-
财政年份:2014
-
负责人:Lovick Edward Cannon
-
依托单位:
海外基金